|Date||Title and Summary||Additional Format|
|January 10, 2022||
Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts
|January 3, 2022||
Nurix Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.
- Culture & Careers